Paulo Maciag

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma

Shaji Kumar, Jonathan L. Kaufman, Cristina Gasparetto et al. · Blood · 2017 · 517 citations · Full text

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

Shaji Kumar, Simon J. Harrison, Michèle Cavo et al. · The Lancet Oncology · 2020 · 390 citations

Hematological Malignancy, Oncology, Hematology +7

The first clinical use of a live-attenuated Listeria monocytogenes vaccine: A Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix

Paulo Maciag, Siniša Radulović, John Rothman · Vaccine · 2009 · 320 citations

Vaccination, Vaccine Safety, Vaccine Development +9

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM

Philippe Moreau, Asher Chanan‐Khan, Andrew W. Roberts et al. · Blood · 2017 · 271 citations · Full text

Major histocompatibility complex class II polymorphisms and risk of cervical cancer and human papillomavirus infection in Brazilian women.

Paulo Maciag, Nicolas F. Schlecht, Patricia S. A. Souza et al. · PubMed · 2000 · 108 citations

Precancerous Lesions, Genetic Epidemiology, Human Polymorphism +20